Drug Profile
Research programme: small molecule therapeutics - Evotec SE/Facio Therapies
Alternative Names: Facioscapulohumeral muscular dystrophy therapeutics - Evotec SE/Facio Therapies; FSHD therapeutics - Evotec SE/Facio TherapiesLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Evotec AG; Facio Therapies
- Developer Evotec SE; Facio Therapies
- Class Small molecules
- Mechanism of Action DUX4 protein inhibitors; SMCHD1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Facioscapulohumeral muscular dystrophy
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Facioscapulohumeral-muscular-dystrophy in Germany
- 28 Aug 2021 No recent reports of development identified for research development in Facioscapulohumeral-muscular-dystrophy in Netherlands
- 29 Jul 2019 Research development in Facioscapulohumeral muscular dystrophy is ongoing in Germany and Netherlands (Evotec pipeline, July 2019)